Published in Nature on February 03, 2013
Inflammation-induced cancer: crosstalk between tumours, immune cells and microorganisms. Nat Rev Cancer (2013) 4.02
In vivo RNAi screening identifies a mechanism of sorafenib resistance in liver cancer. Nat Med (2014) 2.68
Phosphoenolpyruvate Is a Metabolic Checkpoint of Anti-tumor T Cell Responses. Cell (2015) 2.60
New insights into cancer immunoediting and its three component phases--elimination, equilibrium and escape. Curr Opin Immunol (2014) 2.47
CD4⁺ follicular helper T cell infiltration predicts breast cancer survival. J Clin Invest (2013) 2.18
Mechanisms of disseminated cancer cell dormancy: an awakening field. Nat Rev Cancer (2014) 2.09
Tumour-infiltrating Gr-1+ myeloid cells antagonize senescence in cancer. Nature (2014) 1.88
Restoring immune function of tumor-specific CD4+ T cells during recurrence of melanoma. J Immunol (2013) 1.53
Large-scale genetic study in East Asians identifies six new loci associated with colorectal cancer risk. Nat Genet (2014) 1.49
Engineering synthetic vaccines using cues from natural immunity. Nat Mater (2013) 1.48
Adaptive Immune Regulation of Mammary Postnatal Organogenesis. Dev Cell (2015) 1.48
The antigenic landscape of multiple myeloma: mass spectrometry (re)defines targets for T-cell-based immunotherapy. Blood (2015) 1.47
Recognition of tumors by the innate immune system and natural killer cells. Adv Immunol (2014) 1.27
Type I cytokines synergize with oncogene inhibition to induce tumor growth arrest. Cancer Immunol Res (2014) 1.17
Pathways and therapeutic targets in melanoma. Oncotarget (2014) 1.17
Immune-based antitumor effects of BRAF inhibitors rely on signaling by CD40L and IFNγ. Cancer Res (2014) 1.10
TNF biology, pathogenic mechanisms and emerging therapeutic strategies. Nat Rev Rheumatol (2015) 1.10
The pharmacology of second-generation chimeric antigen receptors. Nat Rev Drug Discov (2015) 1.09
T-cell aging in rheumatoid arthritis. Curr Opin Rheumatol (2014) 1.04
Paradigm Shift in Dendritic Cell-Based Immunotherapy: From in vitro Generated Monocyte-Derived DCs to Naturally Circulating DC Subsets. Front Immunol (2014) 1.04
Molecular characterization of human skin response to diphencyprone at peak and resolution phases: therapeutic insights. J Invest Dermatol (2014) 1.03
Inhibition of ron kinase blocks conversion of micrometastases to overt metastases by boosting antitumor immunity. Cancer Discov (2013) 1.00
Balancing the innate immune system in tumor development. Trends Cell Biol (2014) 0.98
Orchestration of angiogenesis by immune cells. Front Oncol (2014) 0.97
Trial Watch: Immunostimulatory cytokines. Oncoimmunology (2013) 0.96
Quantitative measurement of melanoma spread in sentinel lymph nodes and survival. PLoS Med (2014) 0.95
Combination of platelet to lymphocyte ratio and neutrophil to lymphocyte ratio is a useful prognostic factor in advanced non-small cell lung cancer patients. Thorac Cancer (2015) 0.95
Consensus nomenclature for CD8(+) T cell phenotypes in cancer. Oncoimmunology (2015) 0.94
Utilizing cytokines to function-enable human NK cells for the immunotherapy of cancer. Scientifica (Cairo) (2014) 0.94
Innate immune sensing of cytosolic chromatin fragments through cGAS promotes senescence. Nat Cell Biol (2017) 0.94
IL-6-STAT3 signaling and premature senescence. JAKSTAT (2013) 0.93
Role of lymphocytes in liver cancer. Oncoimmunology (2013) 0.93
Characterization of distinct immunophenotypes across pediatric brain tumor types. J Immunol (2013) 0.92
Depletion of the transcriptional coactivators megakaryoblastic leukaemia 1 and 2 abolishes hepatocellular carcinoma xenograft growth by inducing oncogene-induced senescence. EMBO Mol Med (2013) 0.92
From mice to humans: developments in cancer immunoediting. J Clin Invest (2015) 0.90
IFNγ induces oxidative stress, DNA damage and tumor cell senescence via TGFβ/SMAD signaling-dependent induction of Nox4 and suppression of ANT2. Oncogene (2015) 0.90
JUNB/AP-1 controls IFN-γ during inflammatory liver disease. J Clin Invest (2013) 0.89
Enlarged memory T-cell pool and enhanced Th1-type responses in chronic myeloid leukemia patients who have successfully discontinued IFN-α monotherapy. PLoS One (2014) 0.89
IL-4 abrogates T(H)17 cell-mediated inflammation by selective silencing of IL-23 in antigen-presenting cells. Proc Natl Acad Sci U S A (2015) 0.88
Small cell lung cancer cells express the late stage gBK tumor antigen: a possible immunotarget for the terminal disease. Am J Transl Res (2014) 0.88
CD160 is essential for NK-mediated IFN-γ production. J Exp Med (2015) 0.87
α-Fucosidase as a novel convenient biomarker for cellular senescence. Cell Cycle (2013) 0.86
Immune surveillance of unhealthy cells by natural killer cells. Cold Spring Harb Symp Quant Biol (2013) 0.86
CD8+ T cell-independent tumor regression induced by Fc-OX40L and therapeutic vaccination in a mouse model of glioma. J Immunol (2013) 0.85
In vitro evidence for senescent multinucleated melanocytes as a source for tumor-initiating cells. Cell Death Dis (2015) 0.84
Tumor necrosis factor is dispensable for the success of immunogenic anticancer chemotherapy. Oncoimmunology (2013) 0.84
IL-6-mediated environmental conditioning of defective Th1 differentiation dampens antitumour immune responses in old age. Nat Commun (2015) 0.84
Autoimmunity as a double agent in tumor killing and cancer promotion. Front Immunol (2014) 0.83
Cellular senescence: from growth arrest to immunogenic conversion. Age (Dordr) (2015) 0.82
Multivalent presentation of MPL by porous silicon microparticles favors T helper 1 polarization enhancing the anti-tumor efficacy of doxorubicin nanoliposomes. PLoS One (2014) 0.81
64Cu antibody-targeting of the T-cell receptor and subsequent internalization enables in vivo tracking of lymphocytes by PET. Proc Natl Acad Sci U S A (2015) 0.81
A chemogenomic screening identifies CK2 as a target for pro-senescence therapy in PTEN-deficient tumours. Nat Commun (2015) 0.81
Identification of glypican-3-derived long peptides activating both CD8(+) and CD4(+) T cells; prolonged overall survival in cancer patients with Th cell response. Oncoimmunology (2015) 0.81
Association of peripheral leukocyte telomere length and its variation with pancreatic cancer and colorectal cancer risk in Chinese population. Oncotarget (2016) 0.81
Dual therapeutic benefit of electroporation-mediated DNA vaccination in vivo: Enhanced gene transfer and adjuvant activity. Oncoimmunology (2014) 0.80
Assessment of bystander killing-mediated therapy of malignant brain tumors using a multimodal imaging approach. Stem Cell Res Ther (2015) 0.80
Selected cytokine pathways in rheumatoid arthritis. Semin Immunopathol (2017) 0.80
Tumour progression and metastasis. Ecancermedicalscience (2016) 0.79
Cellular and molecular immunology of lung cancer: therapeutic implications. Expert Rev Clin Immunol (2014) 0.79
IFNα induces prolonged remissions modeling curative immunologic responses in chronic myeloid leukemia. Oncoimmunology (2014) 0.79
Clinical and laboratory correlates of lung disease and cancer in adults with idiopathic hypogammaglobulinaemia. Clin Exp Immunol (2016) 0.79
Safety and immunogenicity of the PRAME cancer immunotherapeutic in metastatic melanoma: results of a phase I dose escalation study. ESMO Open (2016) 0.78
Highly efficient IL-21 and feeder cell-driven ex vivo expansion of human NK cells with therapeutic activity in a xenograft mouse model of melanoma. Oncoimmunology (2016) 0.78
Targeting the hallmarks of cancer with therapy-induced endoplasmic reticulum (ER) stress. Mol Cell Oncol (2014) 0.78
IL-7 signaling imparts polyfunctionality and stemness potential to CD4(+) T cells. Oncoimmunology (2016) 0.78
Cellular immunity induced by a recombinant adenovirus- human dendritic cell vaccine for melanoma. J Immunother Cancer (2013) 0.78
Direct tumor recognition by a human CD4(+) T-cell subset potently mediates tumor growth inhibition and orchestrates anti-tumor immune responses. Sci Rep (2015) 0.78
Optimization of a gene electrotransfer procedure for efficient intradermal immunization with an hTERT-based DNA vaccine in mice. Mol Ther Methods Clin Dev (2014) 0.78
Cancer-targeted IL-12 controls human rhabdomyosarcoma by senescence induction and myogenic differentiation. Oncoimmunology (2015) 0.78
TLR9 re-expression in cancer cells extends the S-phase and stabilizes p16(INK4a) protein expression. Oncogenesis (2016) 0.78
Association of soluble tumor necrosis factor receptors 1 and 2 with nephropathy, cardiovascular events, and total mortality in type 2 diabetes. Cardiovasc Diabetol (2016) 0.78
Personalized peptide vaccines and their relation to other therapies in urological cancer. Nat Rev Urol (2017) 0.77
Priming of Qualitatively Superior Human Effector CD8+ T Cells Using TLR8 Ligand Combined with FLT3 Ligand. J Immunol (2015) 0.77
Circulating and tumor-infiltrating mucosal associated invariant T (MAIT) cells in colorectal cancer patients. Sci Rep (2016) 0.77
Metronomic topotecan impedes tumor growth of MYCN-amplified neuroblastoma cells in vitro and in vivo by therapy induced senescence. Oncotarget (2016) 0.77
Long-lasting multifunctional CD8(+) T cell responses in end-stage melanoma patients can be induced by dendritic cell vaccination. Oncoimmunology (2015) 0.77
Rapid generation of NY-ESO-1-specific CD4(+) THELPER1 cells for adoptive T-cell therapy. Oncoimmunology (2015) 0.77
Adjuvant cationic liposomes presenting MPL and IL-12 induce cell death, suppress tumor growth, and alter the cellular phenotype of tumors in a murine model of breast cancer. Mol Pharm (2014) 0.77
Evaluation of innate and adaptive immunity contributing to the antitumor effects of PD1 blockade in an orthotopic murine model of pancreatic cancer. Oncoimmunology (2016) 0.77
The promising alliance of anti-cancer electrochemotherapy with immunotherapy. Cancer Metastasis Rev (2016) 0.77
The Nuclear Orphan Receptor NR2F6 Is a Central Checkpoint for Cancer Immune Surveillance. Cell Rep (2015) 0.77
Hepatocellular carcinoma repression by TNFα-mediated synergistic lethal effect of mitosis defect-induced senescence and cell death sensitization. Hepatology (2016) 0.77
Cutaneous immunology: basics and new concepts. Semin Immunopathol (2015) 0.77
Sodium channel γENaC mediates IL-17 synergized high salt induced inflammatory stress in breast cancer cells. Cell Immunol (2015) 0.76
Nod1 Limits Colitis-Associated Tumorigenesis by Regulating IFN-γ Production. J Immunol (2016) 0.76
Tumour-specific CD4 T cells eradicate melanoma via indirect recognition of tumour-derived antigen. Immunol Cell Biol (2016) 0.76
Changing T-cell enigma: cancer killing or cancer control? Cell Cycle (2013) 0.76
Adaptive Immunity to Leukemia Is Inhibited by Cross-Reactive Induced Regulatory T Cells. J Immunol (2015) 0.76
STAT2 Is a Pervasive Cytokine Regulator due to Its Inhibition of STAT1 in Multiple Signaling Pathways. PLoS Biol (2016) 0.76
Monitoring the Bystander Killing Effect of Human Multipotent Stem Cells for Treatment of Malignant Brain Tumors. Stem Cells Int (2016) 0.76
Cytokine-induced 'bystander' senescence in DDR and immuno-surveillance. Oncotarget (2013) 0.76
Proportions of blood-borne Vδ1+ and Vδ2+ T-cells are associated with overall survival of melanoma patients treated with ipilimumab. Eur J Cancer (2016) 0.76
Aberrant 5'-CpG Methylation of Cord Blood TNFα Associated with Maternal Exposure to Polybrominated Diphenyl Ethers. PLoS One (2015) 0.76
Epigenome rejuvenation: HP1β mobility as a measure of pluripotent and senescent chromatin ground states. Sci Rep (2014) 0.76
Tumor-infiltrating myeloid cells drive senescence evasion and chemoresistance in tumors. Oncoimmunology (2015) 0.76
Epstein-Barr Virus BZLF1-Mediated Downregulation of Proinflammatory Factors Is Essential for Optimal Lytic Viral Replication. J Virol (2015) 0.76
Escalating regulation of 5T4-specific IFN-γ(+) CD4(+) T cells distinguishes colorectal cancer patients from healthy controls and provides a target for in vivo therapy. Cancer Immunol Res (2013) 0.76
Tumor cell secretion of soluble factor(s) for specific immunosuppression. Sci Rep (2015) 0.76
CTLs regulate tumor growth via cytostatic effects rather than cytotoxicity: a few T cells can influence the growth of many times more tumor cells. Oncoimmunology (2014) 0.76
Identification of novel Lck-derived T helper epitope long peptides applicable for HLA-A2(+) cancer patients as cancer vaccine. Cancer Sci (2015) 0.76
Hallmarks of cancer: the next generation. Cell (2011) 140.01
Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med (2010) 67.34
Cancer regression in patients after transfer of genetically engineered lymphocytes. Science (2006) 16.96
Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature (2007) 16.95
Cellular senescence: when bad things happen to good cells. Nat Rev Mol Cell Biol (2007) 16.55
Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science (2011) 15.79
Mice deficient for the 55 kd tumor necrosis factor receptor are resistant to endotoxic shock, yet succumb to L. monocytogenes infection. Cell (1993) 9.84
Heritable formation of pancreatic beta-cell tumours in transgenic mice expressing recombinant insulin/simian virus 40 oncogenes. Nature (1985) 9.78
Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines. J Natl Cancer Inst (1991) 9.39
Oncogene-induced senescence relayed by an interleukin-dependent inflammatory network. Cell (2008) 9.22
Oncogene-induced senescence as an initial barrier in lymphoma development. Nature (2005) 9.16
Probing tumor phenotypes using stable and regulated synthetic microRNA precursors. Nat Genet (2005) 8.99
Humanized mice in translational biomedical research. Nat Rev Immunol (2007) 8.83
Adaptive immunity maintains occult cancer in an equilibrium state. Nature (2007) 8.14
Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1. N Engl J Med (2008) 7.80
Chemokine signaling via the CXCR2 receptor reinforces senescence. Cell (2008) 7.65
Senescence in tumours: evidence from mice and humans. Nat Rev Cancer (2010) 6.34
Senescence surveillance of pre-malignant hepatocytes limits liver cancer development. Nature (2011) 6.14
The central role of CD4(+) T cells in the antitumor immune response. J Exp Med (1998) 6.02
Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. N Engl J Med (2009) 5.79
Cancer immunology. N Engl J Med (2008) 5.22
gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. N Engl J Med (2011) 5.15
Effects of angiogenesis inhibitors on multistage carcinogenesis in mice. Science (1999) 4.91
Sporadic immunogenic tumours avoid destruction by inducing T-cell tolerance. Nature (2005) 3.70
CD4(+) T cells contribute to the remodeling of the microenvironment required for sustained tumor regression upon oncogene inactivation. Cancer Cell (2010) 3.33
p63 deficiency activates a program of cellular senescence and leads to accelerated aging. Genes Dev (2005) 3.02
Decreased tumor surveillance in perforin-deficient mice. J Exp Med (1996) 3.00
Transgenic Polyoma middle-T mice model premalignant mammary disease. Cancer Res (2001) 2.97
Pro-senescence therapy for cancer treatment. Nat Rev Cancer (2011) 2.75
Natural killer cells activated by MHC class I(low) targets prime dendritic cells to induce protective CD8 T cell responses. Immunity (2003) 2.03
Mast cells control neutrophil recruitment during T cell-mediated delayed-type hypersensitivity reactions through tumor necrosis factor and macrophage inflammatory protein 2. J Exp Med (2000) 2.00
TNFR1 signaling and IFN-gamma signaling determine whether T cells induce tumor dormancy or promote multistage carcinogenesis. Cancer Cell (2008) 1.91
IFN-gamma- and TNF-dependent bystander eradication of antigen-loss variants in established mouse cancers. J Clin Invest (2008) 1.71
Impaired interferon signaling is a common immune defect in human cancer. Proc Natl Acad Sci U S A (2009) 1.66
Limited capacity for tolerization of CD4+ T cells specific for a pancreatic beta cell neo-antigen. Immunity (1995) 1.52
A comprehensive antibody panel for immunohistochemical analysis of formalin-fixed, paraffin-embedded hematopoietic neoplasms of mice: analysis of mouse specific and human antibodies cross-reactive with murine tissue. Toxicol Pathol (2007) 1.15
Genetic associations of 115 polymorphisms with cancers of the upper aerodigestive tract across 10 European countries: the ARCAGE project. Cancer Res (2009) 1.12
Overexpression of kinase-negative protein kinase Cdelta in pancreatic beta-cells protects mice from diet-induced glucose intolerance and beta-cell dysfunction. Diabetes (2009) 1.07
Early tumor dissemination, but late metastasis: insights into tumor dormancy. J Clin Invest (2010) 1.06
EpCAM, a human tumor-associated antigen promotes Th2 development and tumor immune evasion. Blood (2009) 1.06
Incomplete inhibition of the Rb tumor suppressor pathway in the context of inactivated p53 is sufficient for pancreatic islet tumorigenesis. Oncogene (2005) 1.02
Direct crosstalk between mast cell-TNF and TNFR1-expressing endothelia mediates local tissue inflammation. Blood (2009) 0.98
Pancreatic β-cells activate a JunB/ATF3-dependent survival pathway during inflammation. Oncogene (2011) 0.96
A microRNA component of the p53 tumour suppressor network. Nature (2007) 19.25
Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature (2007) 16.95
Human lymphoid and myeloid cell development in NOD/LtSz-scid IL2R gamma null mice engrafted with mobilized human hemopoietic stem cells. J Immunol (2005) 9.76
Senescence of activated stellate cells limits liver fibrosis. Cell (2008) 8.98
Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi. Nature (2008) 8.42
Treating childhood acute lymphoblastic leukemia without cranial irradiation. N Engl J Med (2009) 7.95
Senescence surveillance of pre-malignant hepatocytes limits liver cancer development. Nature (2011) 6.14
Identification and characterization of metabolically benign obesity in humans. Arch Intern Med (2008) 5.74
Simultaneous PET-MRI: a new approach for functional and morphological imaging. Nat Med (2008) 4.54
An accurate risk score based on anthropometric, dietary, and lifestyle factors to predict the development of type 2 diabetes. Diabetes Care (2007) 4.14
Glimepiride combined with morning insulin glargine, bedtime neutral protamine hagedorn insulin, or bedtime insulin glargine in patients with type 2 diabetes. A randomized, controlled trial. Ann Intern Med (2003) 4.11
Resting dendritic cells induce peripheral CD8+ T cell tolerance through PD-1 and CTLA-4. Nat Immunol (2005) 4.01
Analysis of risk factors determining prognosis of cutaneous squamous-cell carcinoma: a prospective study. Lancet Oncol (2008) 3.71
Apoptotic cells induce migration of phagocytes via caspase-3-mediated release of a lipid attraction signal. Cell (2003) 3.68
A humanized version of Foxp2 affects cortico-basal ganglia circuits in mice. Cell (2009) 3.63
Genomic analysis of the necrotrophic fungal pathogens Sclerotinia sclerotiorum and Botrytis cinerea. PLoS Genet (2011) 3.52
Yes-associated protein is an independent prognostic marker in hepatocellular carcinoma. Cancer (2009) 3.52
A differentiation checkpoint limits hematopoietic stem cell self-renewal in response to DNA damage. Cell (2012) 3.21
Radiation-induced epidermal growth factor receptor nuclear import is linked to activation of DNA-dependent protein kinase. J Biol Chem (2005) 3.02
Granulocytes govern the transcriptional response, morphology and proliferation of Candida albicans in human blood. Mol Microbiol (2005) 3.00
Alpha2-Heremans-Schmid glycoprotein/fetuin-A is associated with insulin resistance and fat accumulation in the liver in humans. Diabetes Care (2006) 2.99
A complex secretory program orchestrated by the inflammasome controls paracrine senescence. Nat Cell Biol (2013) 2.98
Hepatocyte telomere shortening and senescence are general markers of human liver cirrhosis. FASEB J (2002) 2.96
Regulation of apoptosis by alternative pre-mRNA splicing. Mol Cell (2005) 2.89
Determinants of antileukemia effects of allogeneic NK cells. J Immunol (2004) 2.85
A cluster of cooperating tumor-suppressor gene candidates in chromosomal deletions. Proc Natl Acad Sci U S A (2012) 2.85
MC1R germline variants confer risk for BRAF-mutant melanoma. Science (2006) 2.84
Causes and metabolic consequences of Fatty liver. Endocr Rev (2008) 2.84
Histopathological diagnostics of malignant melanoma in accordance with the recent AJCC classification 2009: Review of the literature and recommendations for general practice. J Dtsch Dermatol Ges (2011) 2.82
Identification of serum metabolites associated with risk of type 2 diabetes using a targeted metabolomic approach. Diabetes (2012) 2.62
DLC1 is a chromosome 8p tumor suppressor whose loss promotes hepatocellular carcinoma. Genes Dev (2008) 2.60
Cytoplasmic poly(adenosine diphosphate-ribose) polymerase expression is predictive and prognostic in patients with breast cancer treated with neoadjuvant chemotherapy. J Clin Oncol (2011) 2.56
Identification of a therapeutic strategy targeting amplified FGF19 in liver cancer by Oncogenomic screening. Cancer Cell (2011) 2.56
Prospective evaluation of a follow-up schedule in cutaneous melanoma patients: recommendations for an effective follow-up strategy. J Clin Oncol (2003) 2.56
Functional identification of tumor-suppressor genes through an in vivo RNA interference screen in a mouse lymphoma model. Cancer Cell (2009) 2.54
Tissue-specific and reversible RNA interference in transgenic mice. Nat Genet (2007) 2.54
Topoisomerase levels determine chemotherapy response in vitro and in vivo. Proc Natl Acad Sci U S A (2008) 2.53
Performance test of an LSO-APD detector in a 7-T MRI scanner for simultaneous PET/MRI. J Nucl Med (2006) 2.52
Prospective biopsy-controlled evaluation of cell death biomarkers for prediction of liver fibrosis and nonalcoholic steatohepatitis. Hepatology (2011) 2.49
Plasmablastic lymphoma and related disorders. Am J Clin Pathol (2011) 2.44
Expression of therapeutic proteins after delivery of chemically modified mRNA in mice. Nat Biotechnol (2011) 2.43
Plasma fetuin-A levels and the risk of type 2 diabetes. Diabetes (2008) 2.41
Detection of apoptotic caspase activation in sera from patients with chronic HCV infection is associated with fibrotic liver injury. Hepatology (2004) 2.41
Dissociation between fatty liver and insulin resistance in humans carrying a variant of the patatin-like phospholipase 3 gene. Diabetes (2009) 2.36
In vivo transcript profiling of Candida albicans identifies a gene essential for interepithelial dissemination. Cell Microbiol (2007) 2.35
Nucleic acid-sensing Toll-like receptors are essential for the control of endogenous retrovirus viremia and ERV-induced tumors. Immunity (2012) 2.35
Changes of the plasma metabolome during an oral glucose tolerance test: is there more than glucose to look at? Am J Physiol Endocrinol Metab (2008) 2.32
Reduction of disulphide bonds unmasks potent antimicrobial activity of human β-defensin 1. Nature (2011) 2.31
EZH2 is a mediator of EWS/FLI1 driven tumor growth and metastasis blocking endothelial and neuro-ectodermal differentiation. Proc Natl Acad Sci U S A (2009) 2.25
Germ-line mutations in p27Kip1 cause a multiple endocrine neoplasia syndrome in rats and humans. Proc Natl Acad Sci U S A (2006) 2.24
MicroRNAs play a role in spontaneous recovery from acute liver failure. Hepatology (2014) 2.23
Survival after intratumoral interleukin-2 treatment of 72 melanoma patients and response upon the first chemotherapy during follow-up. Cancer Immunol Immunother (2010) 2.18
Early graft failure of small-sized porcine valved conduits in reconstruction of the right ventricular outflow tract. Ann Thorac Surg (2006) 2.18
Polymorphisms within novel risk loci for type 2 diabetes determine beta-cell function. PLoS One (2007) 2.16
Liver cell death and anemia in Wilson disease involve acid sphingomyelinase and ceramide. Nat Med (2007) 2.14
Detectable minimal residual disease before hematopoietic cell transplantation is prognostic but does not preclude cure for children with very-high-risk leukemia. Blood (2012) 2.14
Prognostic value of minimal residual disease quantification before allogeneic stem-cell transplantation in relapsed childhood acute lymphoblastic leukemia: the ALL-REZ BFM Study Group. J Clin Oncol (2008) 2.08
Human CD271-positive melanoma stem cells associated with metastasis establish tumor heterogeneity and long-term growth. Cancer Res (2011) 2.08
Fifteen-year single center experience with the "Giessen Hybrid" approach for hypoplastic left heart and variants: current strategies and outcomes. Pediatr Cardiol (2014) 2.08
Plasma fetuin-a levels and the risk of myocardial infarction and ischemic stroke. Circulation (2008) 2.08
Adoptive transfer of epstein-barr virus (EBV) nuclear antigen 1-specific t cells as treatment for EBV reactivation and lymphoproliferative disorders after allogeneic stem-cell transplantation. J Clin Oncol (2012) 2.07
Activation and caspase-mediated inhibition of PARP: a molecular switch between fibroblast necrosis and apoptosis in death receptor signaling. Mol Biol Cell (2002) 2.05
Adoptive transfer of autologous, HER2-specific, cytotoxic T lymphocytes for the treatment of HER2-overexpressing breast cancer. Cancer Immunol Immunother (2007) 2.05
Natural killer cells activated by MHC class I(low) targets prime dendritic cells to induce protective CD8 T cell responses. Immunity (2003) 2.03
Mechanisms of suicidal erythrocyte death. Cell Physiol Biochem (2005) 2.02
Hepatic lipid composition and stearoyl-coenzyme A desaturase 1 mRNA expression can be estimated from plasma VLDL fatty acid ratios. Clin Chem (2009) 2.02
Fetuin-A induces cytokine expression and suppresses adiponectin production. PLoS One (2008) 2.02
IAPs contain an evolutionarily conserved ubiquitin-binding domain that regulates NF-kappaB as well as cell survival and oncogenesis. Nat Cell Biol (2008) 1.97
Increased hepatotoxicity of tumor necrosis factor-related apoptosis-inducing ligand in diseased human liver. Hepatology (2007) 1.97
Involvement of TRAIL and its receptors in viral hepatitis. FASEB J (2002) 1.97
Cancer progression and tumor cell motility are associated with the FGFR4 Arg(388) allele. Cancer Res (2002) 1.95
Safe adoptive transfer of virus-specific T-cell immunity for the treatment of systemic adenovirus infection after allogeneic stem cell transplantation. Br J Haematol (2006) 1.94
Outcome in psychogenic nonepileptic seizures: 1 to 10-year follow-up in 164 patients. Ann Neurol (2003) 1.93
Introducing the German Mouse Clinic: open access platform for standardized phenotyping. Nat Methods (2005) 1.93
Comparison of killer Ig-like receptor genotyping and phenotyping for selection of allogeneic blood stem cell donors. J Immunol (2005) 1.92
Selection of stem cells by using antibodies that target different CD34 epitopes yields different patterns of T-cell differentiation. Stem Cells (2006) 1.91
Antineutrophil cytoplasmic autoantibodies against the murine homolog of proteinase 3 (Wegener autoantigen) are pathogenic in vivo. Blood (2004) 1.91
TNFR1 signaling and IFN-gamma signaling determine whether T cells induce tumor dormancy or promote multistage carcinogenesis. Cancer Cell (2008) 1.91
The siderophore iron transporter of Candida albicans (Sit1p/Arn1p) mediates uptake of ferrichrome-type siderophores and is required for epithelial invasion. Infect Immun (2002) 1.91
Impact of age on the relationships of brown adipose tissue with sex and adiposity in humans. Diabetes (2010) 1.90
Plant infection and the establishment of fungal biotrophy. Trends Plant Sci (2002) 1.89
Skp2-dependent degradation of p27kip1 is essential for cell cycle progression. Genes Dev (2004) 1.88
Deregulated MYC expression induces dependence upon AMPK-related kinase 5. Nature (2012) 1.88
Interleukin-4 therapy of psoriasis induces Th2 responses and improves human autoimmune disease. Nat Med (2002) 1.86
A Direct in vivo RNAi screen identifies MKK4 as a key regulator of liver regeneration. Cell (2013) 1.86
Proteins of nucleotide and base excision repair pathways interact in mitochondria to protect from loss of subcutaneous fat, a hallmark of aging. J Exp Med (2010) 1.86